4//SEC Filing
New Leaf Venture Management III, L.L.C. 4
Accession 0000899243-19-022047
CIK 0001654151other
Filed
Aug 18, 8:00 PM ET
Accepted
Aug 19, 4:35 PM ET
Size
25.2 KB
Accession
0000899243-19-022047
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2019-08-16$36.54/sh−75,974$2,776,341→ 1,991,884 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$36.54/sh−69,292$2,532,158→ 1,816,990 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−78,450$2,831,347→ 2,067,858 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−28,626$1,059,586→ 1,963,258 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−71,550$2,582,318→ 1,886,282 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−26,108$966,382→ 1,790,882 total(indirect: See Footnote)
New Leaf Ventures III, L.P.
10% Owner
Transactions
- Sale
Common Stock
2019-08-16$36.54/sh−69,292$2,532,158→ 1,816,990 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−78,450$2,831,347→ 2,067,858 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−28,626$1,059,586→ 1,963,258 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$36.54/sh−75,974$2,776,341→ 1,991,884 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−71,550$2,582,318→ 1,886,282 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−26,108$966,382→ 1,790,882 total(indirect: See Footnote)
Transactions
- Sale
Common Stock
2019-08-15$36.09/sh−71,550$2,582,318→ 1,886,282 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−78,450$2,831,347→ 2,067,858 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−26,108$966,382→ 1,790,882 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$36.54/sh−75,974$2,776,341→ 1,991,884 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$36.54/sh−69,292$2,532,158→ 1,816,990 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−28,626$1,059,586→ 1,963,258 total(indirect: See Footnote)
Transactions
- Sale
Common Stock
2019-08-16$37.01/sh−26,108$966,382→ 1,790,882 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−78,450$2,831,347→ 2,067,858 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$36.54/sh−75,974$2,776,341→ 1,991,884 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−28,626$1,059,586→ 1,963,258 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−71,550$2,582,318→ 1,886,282 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$36.54/sh−69,292$2,532,158→ 1,816,990 total(indirect: See Footnote)
New Leaf BPO Associates I, L.P.
10% Owner
Transactions
- Sale
Common Stock
2019-08-16$36.54/sh−75,974$2,776,341→ 1,991,884 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−28,626$1,059,586→ 1,963,258 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$36.54/sh−69,292$2,532,158→ 1,816,990 total(indirect: See Footnote) - Sale
Common Stock
2019-08-16$37.01/sh−26,108$966,382→ 1,790,882 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−71,550$2,582,318→ 1,886,282 total(indirect: See Footnote) - Sale
Common Stock
2019-08-15$36.09/sh−78,450$2,831,347→ 2,067,858 total(indirect: See Footnote)
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]The reportable securities are owned directly by New Leaf Ventures III, L.P. ("NLV III"). New Leaf Venture Associates III, L.P. ("NLV Associates III") is the sole general partner of NLV III. New Leaf Venture Management III, L.L.C. ("NLV Management III") is the sole general partner of NLV Associates III. New Leaf Venture Partners, L.L.C. ("NLVP") is the investment adviser of NLV III. Each of NLV Associates III and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLV Associates III or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3](Continuation from footnote 2) Each of Ronald M. Hunt and Vijay K. Lathi (each, a "Member" and collectively, the "Members") is a member of NLV Management III and may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
- [F6]The reportable securities are owned directly by New Leaf Biopharma Opportunities I, L.P. ("Biopharma I"). New Leaf BPO Associates I, L.P. ("NLBA I") is the sole general partner of Biopharma I. NLV Management III is the sole general partner of NLBA I. NLVP is the investment adviser of Biopharma I. Each of NLBA I and NLV Management III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA I or NLV Management III are beneficial owners of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F7](Continuation from footnote 6) Each of the Members may be deemed to have shared voting and dispositive power of these securities. Each of the Members disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Documents
Issuer
Deciphera Pharmaceuticals, Inc.
CIK 0001654151
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001625657
Filing Metadata
- Form type
- 4
- Filed
- Aug 18, 8:00 PM ET
- Accepted
- Aug 19, 4:35 PM ET
- Size
- 25.2 KB